Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study. 

 -  2023 
<br/><br/> Aim: Compare heart failure (HF) costs of Furoscix use at home compared with inpatient intravenous (IV) diuresis. Patients & methods: Prospective, case control study of chronic HF patients presenting to emergency department (ED) with worsening congestion discharged to receive Furoscix 80 mg/10 ml 5-h subcutaneous infusion for <=7 days. 30-day HF-related costs in Furoscix group derived from commercial claims database compared with matched historical patients hospitalized for <72 h. Results: Of 24 Furoscix patients, 1 (4.2%) was hospitalized in 30-day period. 66 control patients identified and were well-matched for age, sex, ejection fraction (EF), renal function and other comorbidities. Furoscix patients had reduced mean per patient HF-related healthcare cost of  
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1479-6678 
<br/><br/><label>Standard No.: </label>10.2217/fca-2023-0071 [doi] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Health Care Costs<br/>*Heart Failure<br/>Case-Control Studies<br/>Diuresis<br/>Heart Failure/dt [Drug Therapy]<br/>Hospitals<br/>Humans<br/>Prospective Studies--Automated
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Health Research Institute
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Research Support, Non-U.S. Gov't